300
Participants
Start Date
December 15, 2021
Primary Completion Date
May 29, 2024
Study Completion Date
May 29, 2024
biomarker-guided strategy
Patients will follow a biomarker-guided strategy based on specific non-invasive biomarkers as defined in EUTRAIN-1 study on the basis of its detection and prediction capacities for rejection at M3 to decide whether a biopsy is performed. At M12 a routine biopsy is performed
Geneva University Hospitals, Geneva
Charité-Universitätsmedizin, Berlin, Berlin
Charité-Universitätsmedizin,, Berlin
Nantes Hospital, Nantes
Saint-Louis Hospital, Paris, Paris
Necker Hospital, Paris, Paris
Vall d'Hebron Hospital, Barcelona
Bellvitge University Hospital, Barcelona
Assistance Publique - Hôpitaux de Paris
OTHER